| Literature DB >> 27774325 |
R M Medrano-Juarez1, D Sotello1, M A Orellana-Barrios1, L D'Cuhna1, J D Payne1, K Nugent1.
Abstract
We present a case of acute hemolytic anemia, renal failure, and Clostridium perfringens bacteremia in a patient with acute myelogenous leukemia. The high fatality of C. perfringens bacteremia requires that clinicians recognize and rapidly treat patients at risk for this infection. Although other hemolytic processes are in the differential diagnosis of these events, the presence of high fever, chills, and rapidly positive blood cultures may help narrow the diagnosis. Most cases of C. perfringens bacteremia have a concomitant coinfection, which makes broad spectrum empiric therapy essential. There is a high mortality rate of C. perfringens infections associated with leukemia.Entities:
Year: 2016 PMID: 27774325 PMCID: PMC5059580 DOI: 10.1155/2016/6549268
Source DB: PubMed Journal: Case Rep Infect Dis
Laboratory values.
| Parameter | Previous | Day of fever | Units |
|---|---|---|---|
| WBC | 0.1 | 0.1 | K/uL |
| RBC | 2.92 | 1.63 | M/uL |
| Hgb | 8.6 | 5.2 | g/dL |
| Hct | 24.1 | 13.7 | % |
| MCV | 82.7 | 84.4 | fL |
| MCH | 29.4 | 31.9 | pg |
| RDW | 12.7 | 13.1 | % |
| Platelet | 16 | 11 | K/uL |
| MPV | 7.7 | 8.9 | fL |
| Na | 137 | 130 | mmol/L |
| K | 3.8 | 4.9 | mmol/L |
| Cl | 100 | 96 | mmol/L |
| Mg | 1.6 | 1.5 | mg/dL |
| Ca | 8.8 | 8 | mg/dL |
| Ph | 3.7 | 2 | mg/dL |
| Bicarb | 25 | 20 | mmol/L |
| BUN | 15 | 37 | mg/dL |
| Creatinine | 1.2 | 2.4 | mg/dL |
| Uric acid | 4.3 | mg/dL | |
| Total bilirubin | 1.7 | 13.4 | mg/dL |
| Direct bilirubin | 8.3 | mg/dL | |
| LDH | 120 | 1132 | IU/L |
| ALT | 97 | 130 | IU/L |
| AST | 167 | 36 | IU/L |
| PT | 18 | seg | |
| INR | 1.6 | ||
| PTT | 58.2 | sec | |
| Fibrinogen | 517 | mg/dL | |
| D dimer | 6200 | ng/mL | |
| Coombs | Positive | ||
| Haptoglobin | <15 | mg/dL | |
| vWF protease activity | 64 | % |
| Authors | Age | Sex | Leukemia type | Survival |
|---|---|---|---|---|
| Ifthikaruddin and Holmes [ | 54 | F | AML | N |
| van Bunderen et al. [ | 73 | F | CLL | N |
| Vaiopoulos et al. [ | 74 | M | AML | N |
| Pirrotta et al. [ | 50 | M | ALL | N |
| Kapoor et al. [ | 58 | M | AML | N |
| Bodey et al. [ | 30 | F | NSAL | N |
| 27 | F | NSAL | N | |
| 47 | M | NSAL | Y | |
| 64 | M | NSAL | N | |
| 53 | F | NSAL | N | |
| 58 | F | NSAL | N | |
| 50 | M | NSAL | N | |
| 37 | M | NSAL | N | |
| 20 | M | NSAL | Y | |
| 53 | M | NSAL | N | |
| 19 | M | NSAL | N | |
| 60 | M | NSAL | N | |
| 19 | F | NSAL | N | |
| Lee et al. [ | 57 | M | ALL | N |
| Our case | 32 | M | AML | Y |
AML: acute myelogenous leukemia; CLL: chronic lymphocytic leukemia; NSAL: nonspecified acute leukemia; ALL: acute lymphocytic leukemia; N: no survival; Y: survival.